Adocia
115 avenue Lacassagne
Lyon
69003
France
Tel: +33-(0)4-72-610-610
Fax: +33-(0)4-72-363-967
Website: http://www.adocia.com/
About Adocia
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.YEAR FOUNDED:
December 2005
LEADERSHIP:
Founders: Gérard Soula, Olivier Soula, and Rémi Soula
CEO: Gérard Soula
CFO: Valérie Danaguezian
JOBS:
Please click here for Adocia job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
117 articles about Adocia
-
Adocia Announces New BioChaperone Program Combining A Basal Insulin And GLP-1s
9/7/2016
-
Adocia's Foot Ulcer Med Flunks Phase III Test
8/26/2016
-
Adocia Reinforces Its Focus On Diabetes With The Launch Of A New Project: BioChaperone Glucagon
6/8/2016
-
Adocia To Present Data Validating The Potential Of Biochaperone Technology At The American Diabetes Association 76th Scientific Sessions
6/6/2016
-
Adocia And Eli Lilly Announce Positive Topline Results From A Phase 1b Study Of Repeated Administration Of Ultra-Rapid Biochaperone Lispro U100 In People With Type 2 Diabetes
5/2/2016
-
Adocia Announces First Quarter 2016 Results
4/14/2016
-
Adocia Initiates A Phase 1/2 Clinical Trial On The Post-Meal Effect Of Rapid-Acting Human Insulin, HinsBet U100
4/12/2016
-
Adocia Welcomes Internationally Renowned Diabetes Experts To Inaugural Medical Advisory Board
3/22/2016
-
Adocia Announced Its Financial Results For 2015:
3/17/2016
-
Adocia And Eli Lilly Announce Positive Topline Results From A Phase 1b Study Of Repeated Administration Of Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes
3/15/2016
-
Adocia And Eli Lilly Initiate Phase 1b Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro U100 In Healthy Japanese Subjects
1/29/2016
-
Adocia To Hold Conference Call For Investors To Provide 2015 Annual Business Update And Perspectives For 2016 Thursday December 17, 2015 at 5:45 PM (CET)
12/16/2015
-
Adocia And Eli Lilly Report Positive Results Of A Pilot Bioequivalence Study Comparing Biochaperone Lispro U200 To Biochaperone Lispro U100
12/11/2015
-
Adocia Announces Positive Phase 1b Results Of BioChaperone Combo In Patients With Type 2 Diabetes
11/25/2015
-
Adocia Announces Positive Phase 1b Results On The Post-Meal Effect Of BioChaperone Combo In Patients With Type 1 Diabetes
11/4/2015
-
Adocia Reports Third Quarter 2015 Financial Results
10/13/2015
-
Adocia And Eli Lilly Initiate A Phase 1b Study Evaluating Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes Using Insulin Pump Therapy
10/6/2015
-
Adocia And Eli Lilly Initiate New Phase 1b Study Of Repeated Administration Of Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes
8/27/2015
-
Adocia Presents Financial Results For The First Half Of 2015 Highlighting Strong Growth
7/21/2015
-
Adocia Initiates Two Clinical Studies On Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro, Biochaperone Combo
7/10/2015